Dr Karine Mardon obtained her PhD in radiopharmacology from University Paris XII in 1994; she then moved to Australia to pursue postdoctoral studies at ANSTO in the Radiopharmaceutical Division and worked there for 5 years in the development and characterisation of radiopharmaceuticals for SPECT and PET. She has extensive experience with in vitro and in vivo preclinical research, particularly in the evaluation of drugs developed for the study of movement disorders as well as in the evaluation of radiolabelled peripheral benzodiazepine receptor ligands as markers of neurodegeneration and tumour occurrence. She moved to Brisbane in 2000 and joined the University of Queensland where she developed further experience working in the field of preclinical drug development in the ADME division of TetraQ. She joined the Centre for Advanced Imaging in October 2010 as NIF Facility Fellow for preclinical PET/CT.
NIF is hiring: As the Scientific Project Manager, you will be instrumental in driving the successful delivery of key initiatives within the National Imaging Facility.
10 September 2024
“You walk in, and in less than a second, your total body is imaged…
05 September 2024
The groundbreaking Australian Mild Traumatic Brain Injury (AUS-mTBI) study will see thousands of volunteers from across the country who have had a recent concussion have the option to opt-in to repo
01 August 2024
NIF-supported projects, MRtrix3 and ACRF Australian Centre of Excellence in Melanoma Imaging and Diagnosis have been announced as Finalists in the 2024 Australian Museum Eureka Prizes.
31 July 2024